NImmune and BioTherapeutics Form Strategic Alliance to Accelerate Precision Medicine Development for Autoimmune Diseases
Key Insights
NImmune Biopharma (search) partners with BioTherapeutics (search) to enhance precision immunology capabilities through advanced preclinical services and regulatory expertise.
The collaboration will utilize BioTherapeutics (search)' sophisticated animal models, including pig models for inflammatory bowel disease (search), and computational platforms for drug development.
This partnership expands NImmune's R&D ecosystem, building on their successful track record with NIMML Institute (search) that led to the development and AbbVie (search) acquisition of NX-13.
NImmune Biopharma (search) has established a strategic research partnership with BioTherapeutics (search) to accelerate the development of innovative precision medicines targeting inflammatory and autoimmune conditions. This collaboration marks a significant advancement in precision immunology research, combining NImmune's therapeutic development expertise with BioTherapeutics' comprehensive preclinical and regulatory capabilities.
Expanding Preclinical Development Capabilities
The partnership provides NImmune access to BioTherapeutics (search)' sophisticated preclinical infrastructure, including specialized pig models for inflammatory bowel disease (search) and advanced pharmacokinetics/pharmacodynamics analysis capabilities. These resources will be crucial for mechanism of action validation studies and the development of both animal and computational models for autoimmune and inflammatory diseases.
Dr. Raquel Hontecillas, Chief Scientific Officer at BioTherapeutics (search), emphasized the significance of the collaboration: "We are excited to collaborate across teams in support of the development of much-needed therapeutics by providing our highly sophisticated computational and preclinical services, including our proprietary efficacy animal models of autoimmune and inflammatory disease."
Creating a Comprehensive R&D Ecosystem
This new alliance complements NImmune's existing collaboration with the NIMML Institute (search), creating a robust scientific innovation ecosystem. The integrated approach has already demonstrated success through the development of NX-13, which was subsequently acquired by AbbVie (search), validating the effectiveness of their collaborative model.
Dr. Josep Bassaganya-Riera, NImmune's founder and CEO, highlighted the strategic importance of the partnership: "Through NImmune's strategic partnerships with both the NIMML Institute (search) and BioTherapeutics (search), we have created a best-in-class scientific ecosystem capable of accelerating the pipeline — from AI-enabled target discovery and validation using the TITAN-X platform to preclinical animal modelling to clinical testing and ultimately commercialisation."
Advancing Drug Development Efficiency
The partnership leverages BioTherapeutics (search)' specialized regulatory infrastructure for product testing, creating a unique drug development ecosystem in Blacksburg. This integrated approach aims to develop safer and more effective therapeutics at an accelerated pace, addressing critical unmet needs in inflammatory and autoimmune disease treatment.
The collaboration enables transdisciplinary teams to work seamlessly across various development phases, from initial discovery through clinical testing. This comprehensive approach is designed to streamline the development process while maintaining rigorous scientific standards and regulatory compliance.